



Ellen T. Matloff

EDUCATION

1991-1993 M.S. Genetic Counseling
Northwestern University, Chicago, IL

1987-1991 B.S. Biology, cum laude
Union College, Schenectady, NY

CERTIFICATION

1996 American Board of Genetic Counseling

NATIONAL MEMBERSHIPS

American Society of Human Genetics
American Society of Clinical Oncology
National Society of Genetic Counselors

PROFESSIONAL EXPERIENCE

2014- President and CEO
My Gene Counsel, LLC
North Haven, CT

Assistant Clinical Professor
Department of Medical Sciences
Quinnipiac University
Frank H. Netter MD School of Medicine

2007-July 2014 Director, Cancer Genetic Counseling Shared Resource
Yale Cancer Center
New Haven, CT

Research Scientist
Department of Genetics
Yale University School of Medicine
New Haven, CT

1997-2007 Director, Cancer Genetic Counseling Shared Resource
Yale Cancer Center
New Haven, CT

Associate Research Scientist
Department of Genetics
Yale University School of Medicine



New Haven, CT

1995-1997 Cancer Genetic Counselor
Department of Genetics
Yale University School of Medicine
New Haven, CT

1993-1995 Genetic Counselor
Department of Pediatrics
SUNY Health Science Center
Syracuse, NY

PROFESSIONAL ACTIVITIES

2017 Digital Ambassador, National Society of Genetic Counselors
2016-present Member, Working groups for Genomics and Population Health Action Collaborative (An Activity of the Roundtable on Genomics) and Precision Health (The National Academies of Sciences, Engineering, and Medicine)
2015-present Co-Founder, Moderator #GenCSM Tweetchat Series
2012-2014 Member, American College of Surgeons Cancer Program Committee
2010-2013 Schwartz Center Rounds Planning Committee
2008-2009 Member, CT Department of Health ELSI Working Group
2007-2014 Workshop leader, Yale School of Medicine Genetics Course
2006-2014 Course Director, Yale Physician Associate Program's Genetics Module
2004 Item writer, American Board of Genetic Counseling
2001-present Health Care Advisory Board member, FORCE
2000-present Invited Judge, Public Speaking Competition, Yale University
2000-2014 Fellow & Faculty Advisor, Ezra Stiles College, Yale University
2000-2004 Medical Advisory Board Member, Cancersource.com
1997 Invited participant, New York Breast Cancer Study Working Group
1996-1997 Appointed, Co-Chair 1997 National NSGC Cancer Genetics Short Course
1996 Chosen participant, Jane Engelberg Memorial Fellowship Grantsmanship Seminar
1995-present Reviewer, *Journal of Genetic Counseling*, *Archives of Surgery*, *Journal of the National Cancer Institute*, *Clinical Genetics*, *The Breast*, *Cancer*, *Genetic Testing*, *Cancer Epidemiology*, *Biomarkers and Prevention*, *Women's Health*
1994-present Member, Special Interest Group in Cancer Genetics

SPECIAL PROJECTS

2009-2013 Plaintiff
Association for Molecular Pathology, et al. v. Myriad Genetics, Inc., et al.
133 S.Ct. 2107 (2013).
Unanimous Supreme Court Decision, 9-0, banning gene patents.
2009-2014 *Cancer Bytes*



Podcast Series
Matloff, Creator, Interviewer, Director

Fall 2003 *BRCA Carriers: Sharing Stories and Decisions*
Documentary
Matloff, Director

SELECTED PRESENTATIONS

March 2016 Invited Panelist
Public Workshop: “Patient and Medical Professional Perspectives on the Return of Genetic Test Results”
Food and Drug Administration (FDA)
Silver Spring, MD

March 2016 Keynote Speaker
Women in the Biosciences
Jackson Laboratories Bioscience Forum
Farmington, CT

AWARDS

2013 ArtBra New Haven Award Recipient

2013 Farash Scholar, Hobart and William Smith Colleges, Geneva, NY

2011 FORCE: *Spirit of Empowerment Award – Advocacy*
• BRCA Patent Case

2016 UberPITCH, 3rd Place Winner, My Gene Counsel
• Of 275 Start-Up Applicants Nationwide

2017 Watkins Visiting Professor, Wichita State University, Wichita, KS

2017 Finalist, Connecticut Technology Council’s Women of Innovation
Entrepreneurial Innovation and Leadership Category

PUBLICATIONS

Books

1. **Matloff ET.** Handbook of Clinical Cancer Genetics. Cancer Principles & Practice of Oncology. (1st ed.). Philadelphia, Lippincott Williams & Wilkins: 2013.



Book Chapters

1. **Matloff ET**, Li FP, Bale AE. Genetic Counseling. In: DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (5th ed.). Philadelphia, Lippincott - Raven: 1997.
2. **Matloff ET & Bale AE**. Genetic Counseling. In: DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (6th ed.). Philadelphia, Lippincott-Raven: 2001
3. **Matloff ET**. Genetic Counseling. In: DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (7th ed.). Philadelphia, Lippincott-Raven: 2005.
4. **Matloff ET**. Genetic Counseling. In DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (8th ed.). Philadelphia, Lippincott, Williams & Wilkins: 2008
5. **Matloff ET**. Genetic Counseling. In DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (9th ed.). Philadelphia, Lippincott, Williams & Wilkins: 2009
6. **Matloff ET**. Genetic Counseling and Testing for Cancer Survivors. In Kenneth Miller (ed). *Medical and Psychosocial Care of the Cancer Survivor* (1st ed.). Sudbury, Jones and Bartlett: 2010.
7. **Matloff ET**, Bonadies DC. Genetic Counseling. In DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (9th ed.). Philadelphia, Lippincott, Williams & Wilkins: 2011.
8. **Matloff ET**, Barnett RE, Bober SL. Unraveling the Next Chapter: Sexual Development, Body Image, and Sexual Functioning in BRCA Carriers in *Cancer: Principles & Practice of Oncology; Annual Advances in Oncology*, Philadelphia, Lippincott Williams and Wilkins. 2011, 3-6.
9. **Matloff ET**, Bonadies DC. Genetic Risk and the Management of the High-Risk Individual. In Rose MG, DeVita VT, Lawrence TS and Rosenberg SA (eds). *Oncology in Primary Care* (1st ed). Philadelphia, Lippincott, Williams and Wilkins. 2013, 16-23.
10. Bonadies DC, **Matloff ET**. Genetic Counseling. In DeVita VT, Hellman S and Rosenberg SA (eds). *Cancer: Principles and Practice of Oncology* (10th ed.). Philadelphia, Lippincott, Williams & Wilkins: 2014

Patient Articles

1. **Matloff ET**. Counseling BRCA, Lynch Carriers on Prophylactic Oophorectomy. *Oncology NursingNews* 2013; March/April Vol. 7, No.2
2. **Matloff, ET** and Brierley, KL. Should you consider genetic counseling and testing? *Coping with Cancer*. 2014; May/June Issue 28

Guest Editorials

1. Special Issue on Genetic Counseling for Cancer. *The Cancer Journal: The Journal of Principles & Practice of Oncology*; July/ August 2012; 18(4).

Scientific/Medical Articles

1. **Matloff ET.** Practice Variability in Prenatal Genetic Counseling Sessions. *Journal of Genetic Counseling* 1994; 3(3):215-232.
2. **Matloff ET & Zimmerman S.** Framework for a Pro-Active Parent Support Group: The Syracuse Cystic Fibrosis Model. *Journal of Pediatric Health Care* 1996; 10:264-271.
3. **Matloff ET.** Generations Lost: A Cancer Genetics Case Report. *Journal of Genetic Counseling* 1997;6(2):169-172.
4. Harrold EV, Turner BC, **Matloff ET**, Pathare P, Beinfield M, McKhann C, Ward BA, Haffty BG. Local Recurrence in the Conservatively Treated Breast Cancer Patient: A Correlation with Age and Family History. *Cancer Journal from Scientific American* 1998; 4:302-307.
5. **Matloff ET.** Complex Decision-Making for BRCA1/2 Carriers. *The Cancer Journal from Scientific American* 1999; 5(5):266-268.
6. **Matloff ET & Peshkin BN.** Complexities in Cancer Genetic Counseling: Breast and Ovarian Cancer. *PPO Updates* 1998; 12(1):1-11.
7. **Matloff ET**, Peshkin BN, Ward BA. The Impact of Genetic Screening on Surgical Decision Making in Breast Cancer. In: Szabo Z, Lewis JE, Fantini GA, Savalgi RS, eds. *Surgical Technology International VII: International Developments in Surgery and Surgical Research*. San Francisco: *Universal Medical Press; 1998*.
8. Turner BC, Harold E, **Matloff ET**, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG. BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients after Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients with BRCA1/BRCA2 Mutations. *Journal of Clinical Oncology* 1999; 17(10) 3017-3024.
9. **Matloff ET**, Shappell H, Brierley K, Bernhardt B, McKinnon W, Peshkin B. What Would You Do? Specialists' Perspectives on Cancer Genetic Testing, Prophylactic Surgery and Insurance Discrimination. *Journal of Clinical Oncology* 2000; 18(12):2484-2492.
10. **Matloff ET.** The Breast Surgeon's Role in BRCA1 and BRCA2 Testing. *The American Journal of Surgery* 2000; 180:294-298.
11. Shappell HL & **Matloff ET.** Writing Effective Insurance Justification Letters for Cancer Genetic Testing: A Streamlined Approach. *Journal of Genetic Counseling* 2001; 10(4):331-341.
12. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Carter D, Ward BA, **Matloff ET**, Bale AE, Alvarez-Franco M. Conservatively Managed Early Onset Breast Cancer: Outcome as a Function of BRCA1/BRCA2 Germline Mutation Status. *Lancet* 2002; 359(1471).

13. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van 't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, **Matloff ET**, Olopade OI, Weber BL. Reduction in Cancer Risk after Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. *New England Journal of Medicine* 2002; 346:1616-22.
14. Zhou X-P, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, **Matloff ET**, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C. Germline PTEN Promoter Mutations and Deletions in Cowden/Bannayan-Riley-Ruvalcaba Syndrome Result in Aberrant PTEN Protein and Dysregulation of the Phosphoinositol-3-kinase/akt Pathway. *American J Human Genetics* 2003; 73:404-11.
15. King M-C, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. *Science* 2003; 302:643-6.
16. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, **Matloff ET**, Daly MB, Olopade OI, Weber, BL. Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. *Journal of Clinical Oncology* 2004;22(6):1055-1062.
17. **Matloff ET**, Brierley KL, Chimera CM. A Clinician's Guide to Hereditary Colon Cancer. *The Cancer Journal* 2004;10(5):280-7.
18. Claus EB, Petruzella S, **Matloff ET**, Carter D. Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed with Ductal Carcinoma In Situ. *Journal of the American Medical Association* 2005; 293(8):964-9.
19. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, Van 't Veer L, Eeles R, Evans DG, Tomlinson G, **Matloff E**, Narod SA, The PROSE Study Group, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of Short Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 And BRCA2 Mutation Carriers. *Journal of Clinical Oncology* 2005; 23(31): 7804-7810.
20. Higgins SA, **Matloff ET**, Rimm DL, Dziura J, Haffty BG, King BL. Patterns of Reduced Nipple Aspirate Fluid Production and Ductal Lavage Cellularity in Women at High Risk for Breast Cancer. *Breast Cancer Research* 2005; 7(6):1017-1022.
21. Haffty BG, Silber A, **Matloff ET**, Chung J, Lannin D. Racial Differences in the Incidence of BRCA1 and BRCA2 Mutations in a Cohort of Early Onset Breast Cancer Patients: African American Compared to White Women. *Journal of Medical Genetics* 2006; 43:133-137.
22. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, **Matloff ET**, Tomlinson G, Van t'Veer L, Lynch HT, Olopade O, Weber BL, Rebbeck TR. Mortality Reduction After Risk-Reducing Bilateral Salpingo-Oophorectomy in a Prospective Cohort of BRCA1 and BRCA2 Mutation Carriers. *Lancet Oncology* 2006; 7(3): 223-229.
23. **Matloff ET**. Becoming a Daughter. *Journal of Genetic Counseling* 2006; 15(3): 139-143.
24. **Matloff ET**, Moyer A, Shannon KM, Niendorf KB, Col NF. Healthy Women with a Family History of Breast Cancer: Impact of a Tailored Genetic Counseling Intervention on Risk Perception, Knowledge, and Menopausal Therapy Decision-Making. *Journal of Women's Health* 2006; 15(7): 843-856.

-
25. **Matloff ET**, Shannon KM, Moyer A, Col NF. Should Menopausal Women at Increased Risk for Breast Cancer use Tamoxifen, Raloxifene or Hormone Therapy? A Framework for Personalized Risk Assessment and Counseling. *Journal of Cancer Education* 2007; 22(1):10-14.
 26. Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, **Matloff E**, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected BRCA1 and BRCA2 Mutation Carriers. *Clinical Breast Cancer* 2007; 11: 875-882.
 27. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, **Matloff ET**, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1 and BRCA2 Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. *Journal of Clinical Oncology* 2008; 26(8).
 28. **Matloff ET**, Caplan A. Direct to Confusion: Lessons Learned from Marketing BRCA Testing. *American Journal of Bioethics* 2008; 6(8): 5-8.
 29. **Matloff ET**, Bober S, Barnett RE. Unraveling the Next Chapter: Sexual Development, Body Image and Sexual Functioning in Female BRCA Carriers. *The Cancer Journal* 2009; 15(1):15-18.
 30. Haffty BG, Choi DH, Goyal S, Silber A, Ranier K, **Matloff ET**, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS. Breast Cancer in Young Women (YBC): Prevalence of BRCA1/2 Mutations and Risk of Secondary Malignancies Across Diverse Racial Groups. *Annals of Oncology* 2009; 20(10):1653-9.
 31. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin L, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, **Matloff ET**, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. *Cancer Research* 2010; 70(16): 1-7.
 32. **Matloff ET**, Brierley KL. The Double-Helix Derailed: The Story of the BRCA Patent. *The Lancet*, 2010; 376(9738): 314-315.
 33. Brierley KL, Campfield D, Ducaine W, Dohany L, Donenberg T, Shannon K, Schwartz RC, **Matloff ET**. Errors in Delivery of Cancer Genetics Services: Implications for Practice. *Connecticut Medicine*, 2010; 74(7): 413-423.
 34. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, **Matloff ET**, Eeles R, Pichert G, van t'Veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. *JAMA*, 2010; 304(9): 967-975.
 35. **Matloff ET**, Barnett RE. The Growing Role for Genetic Counseling in Endocrinology. *Current Opinion in Oncology*, 2011; 23(1): 28-33.
 36. Campfield Bonadies D, Moyer A, **Matloff ET**. What I Wish I'd Known Before Surgery: BRCA Carriers' Perspectives after Bilateral Salpingo-Oophorectomy. *Fam Cancer*. 2011 Mar; 10 (1):79-85.

-
37. **Matloff ET**, Barnett RE. The Complexities of Genetic Counseling and Testing for Hereditary Colon Cancer. *Semin Colon Rectal Surg*, 2011; 22:95-99.
 38. Pirzadeh Miller S, Bellcross C, Robinson L, **Matloff ET**. Direct to Consumer Genetic Testing: Helpful, Harmful, or Pure Entertainment? *Community Oncology*, 2011; 8: (6) 263-268.
 39. **Matloff, ET**. The Incentive. *Journal of Genetic Counseling*, 2011; 1-2.
 40. Finkelman BS, Rubinstien WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, Veer LV, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, **Matloff E**, Domchek S, Rebbeck TR. Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers. *Journal of Clinical Oncology*, 2012; 1-9.
 41. Brierley KL, Blouch E, Cogswell W, Homer JP, Pencarinha D, Stanislaw CL and **Matloff ET**. Adverse Events in Cancer Genetic Testing: Medical, Ethical, Legal and Financial Implications. *The Cancer Journal: The Journal of Principles & Practice of Oncology*; July/ August 2012; 18(4); 303-309.
 42. **Matloff ET**. From the Guest Editor: Cancer Genetic Counseling and Testing: Past, Present, and Future. *The Cancer Journal: The Journal of Principles & Practice of Oncology*; July/ August 2012; 18(4); 285-286.
 43. **Matloff ET**, Bonadies DC, Moyer A, Brierley KL. Changes in Specialists' Perspectives on Cancer Genetic Testing, Prophylactic Surgery and Insurance Discrimination: Then and Now. *Journal of Genetic Counseling*. July 2013.
 44. Gibson J, Lacy J, **Matloff ET**, and Robert M. Microsatellite Instability Testing in Colorectal Carcinoma: A Practical Guide. *Clinical Gastroenterology and Hepatology*. 2014; 12: 171-176.
 45. **Matloff ET**. What Would Clinicians Do if BRCA or Lynch Positive? Medical Management, Insurance Discrimination, and Confidentiality (based on a presentation) *American Journal of Hematology/Oncology*. 2014; 10:30-32
 46. Brierley KL, Bonadies DC, Moyer A, and **Matloff ET**. "Would you test your children without their consent?" and other sticky dilemmas in the field of cancer genetic testing. *Familial Cancer*. May 2014.
 47. Bonadies DC, Brierley KL, Barnett RE, Baxter MD, Donenberg T, Ducaine WL, Ernst ME, Homer J, Judkins M, Lovick NM, Powers JM, Stanislaw C, Stark E, Stenner C, **Matloff ET**. Adverse Events in Cancer Genetic Testing: The Third Case Series. *Cancer Journal*. 2014;20: 246-253.
 48. Chai X, Friebel TM, Singer CF, Gareth Evans D, Lynch HT, Issacs C, Garber JE, Neuhausen SL, **Matloff E**, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. Published Online: 14 October 2014.



-
49. Doherty J, Bonadies DC, **Matloff ET**. Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Genetics Practice. *J Genetic Counseling*. Published Online: 5 December 2014.
50. Ziai J, **Matloff E**, Choi J, Kombo N, Materin M, Bale AE. Defining the polyposis/colorectal cancer phenotype associated with the Ashkenazi GREM1 duplication: Counseling and management recommendations. *Genet Res, Camb* 2016: 98:1–5.
51. DeLeonardis K, Sedgwick K, Voznesensky O, **Matloff E**, Hofstatter E, Balk S, Tung N. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients. *The Breast Journal* 2017: 1-4.